Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  News  >  Companies  >  All News

News : Companies
Latest NewsCompaniesMarketsEconomy & ForexCommoditiesInterest RatesBusiness LeadersFinance Pro.CalendarSectors

ChromaCode : Raises $10 Million Series C Financing From Adjuvant Capital

share with twitter share with LinkedIn share with facebook
share via e-mail
05/19/2020 | 08:01am EDT

CARLSBAD, Calif., May 19, 2020 /PRNewswire/ -- ChromaCode, Inc., a company redefining molecular testing through data science, today announced a $10 million Series C extension with an investment from Adjuvant Capital. The Adjuvant investment brings the company's total Series C funding to $38 million. Managing Partner Jenny Yip will join ChromaCode's Board of Directors. Funding from this round will support global expansion and continued development of ChromaCode's high-definition PCR platform (HDPCR™), through which the company recently launched a high-throughput SARS-CoV-2 Assay. Adjuvant joins existing ChromaCode investors Northpond Ventures, New Enterprise Associates (NEA), Domain AssociatesWindham Ventures, Okapi VenturesMoore Venture Partners and the California Institute of Technology

Adjuvant Capital invests to accelerate new technology development for the world's most pressing public health challenges and is backed by leading healthcare investors such as the Bill & Melinda Gates Foundation, the International Finance Corporation and Novartis. Adjuvant aims to drive meaningful improvements in the public health of low- and middle-income countries with a focus on neglected, high-burden and emerging infectious diseases, pandemic threats and maternal and child health.

"Real-time PCR is the standard for infectious disease testing, with instruments in use in most laboratories around the globe. The COVID-19 pandemic has intensified the need to leverage this workhorse technology," said Adjuvant's Jenny Yip. "We're excited to work with ChromaCode and support their unique ability to offer affordable, high-throughput assays for diseases of global importance on PCR platforms. We believe ChromaCode's platform will help reduce healthcare costs and improve health outcomes for communities that are resource-challenged in both the developing and developed world."

ChromaCode's platform is built on the use of data science technology — including proprietary signal processing techniques — and cloud computing algorithms to boost the performance of commonly used molecular diagnostics instruments and reagents, setting ChromaCode apart from legacy diagnostics companies. HDPCR expands the number of detectable disease targets in a single reaction using traditional qPCR or dPCR instruments, without any changes to workflow, instrumentation or software. ChromaCode's data-driven approach enhances the performance of traditional diagnostics hardware by as much as 5x, saving time and money on testing that is critical to patient care.

ChromaCode's Co-founder, President and CEO Greg Gosch said, "We are excited to welcome the Adjuvant team and look forward to collaborating with them to deploy our platform wherever it is needed most — including addressing some of the most critical needs in resource-limited communities around the globe."

About ChromaCode
ChromaCode is a software and reagent technology company that uses digital signal processing to dramatically improve clinical molecular analysis. The company's unique core of data scientists and molecular biologists leverage patented mathematical methods and algorithms to extract new information from biochemistry reactions. This approach substantially increases the performance capabilities of today's gold-standard molecular diagnostics platforms at a very low cost. For more information visit ChromaCode.com.

About Adjuvant Capital
Adjuvant is a New York- and San Francisco-based life sciences fund built to accelerate the development of new technologies for the world's most pressing public health challenges. Backed by leading healthcare investors such as the International Finance Corporation, Novartis, and the Bill & Melinda Gates Foundation, Adjuvant draws upon its global network of scientists, public health experts, biopharmaceutical industry veterans, and development finance professionals to identify new investment opportunities. Adjuvant invests in companies developing promising new vaccines, therapeutics, diagnostics and medical devices for historically overlooked indications such as malaria, cholera, Lassa fever and postpartum hemorrhage, with a commitment to make these interventions accessible to those who need them most in low- and middle-income countries.

For more information, visit www.adjuvantcapital.com.

Cision
View original content:http://www.prnewswire.com/news-releases/chromacode-raises-10-million-series-c-financing-from-adjuvant-capital-301061384.html

SOURCE ChromaCode


© PRNewswire 2020
share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news "Companies"
02:06pMajor Attractions in Glenwood Springs Re-open for Business on June 8
GL
02:01pHAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, ALERTS EHEALTH (EHTH) INVESTORS : Important June 8 Deadline, Investors with Losses Should Contact its Attorneys Now
GL
01:01pHAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Alerts iQIYI (IQ) Investors of Lead Plaintiff Deadline in Shareholder Class Action, Urges Investors with Losses to Contact the Firm
GL
12:01pROSEN, A LONGSTANDING AND TOP RANKED FIRM, Reminds Elanco Animal Health Incorporated Investors of Important July 20 Deadline in Securities Class Action; Encourages Investors with Losses in Excess of $100K to Contact the Firm – ELAN
GL
12:01pMONDAY DEADLINE ALERT : Bragar Eagel & Squire, P.C. Reminds Investors That a Class Action Lawsuit Has Been Filed Against Zoom Video Communications, Inc. and Encourages Investors to Contact the Firm
BU
11:51aMANCHESTER UNITED : 'I love Pakistan' tweets Man United's Marcus Rashford
AQ
11:50aMETRO : PHA welcomes cooperation of public, private sector
AQ
11:50aNATIONAL BANK OF PAKISTAN : Currency rates of NBP
AQ
11:50aMASTERCARD : brings Roster of Digital Priceless Experiences to Pakistani Consumers featuring Wasim Akram
AQ
11:49aPAKISTAN INTERNATIONAL AIRLINES : MPs' Salaries and llowances Amendment Bill 2020 tabled in Senate
AQ
Latest news "Companies"